EUCTR2013-002079-16-BE进行中（未招募）不适用
Pharmacokinetics of Caspofungin after one dose in patients with liver failure.
Hospital Erasme0 个研究点开始时间: 2013年7月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All successive patients with liver failure due to alcoholic hepatitis or decompensated cirrhosis admitted in the hospital will be included.
- •The Child Pugh score will determine the inclusion criteria for liver cirrhosis: patient will be included if the score is between 7 and 9 (score B) or between 10 and 15 (score C).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •- Patients with cachexia (Body Mass Index < 18 kg/m²)
- •- Pregnant women
- •- HIV and hepatitis C patients
研究者
相似试验
进行中（未招募）
不适用
Serum pharmacokinetics of Caspofungin in patients with liver failure.The patient admitted for alcoholic hepatitis or decompensated cirrhosis (Child-Pugh score of 10-15) presenting with invasive aspergillosis (proven or probable) and treated by caspofungin.MedDRA version: 14.1Level: LLTClassification code 10024678Term: Liver failureSystem Organ Class: 100000004871EUCTR2012-004031-23-BEHopital Erasme
已完成
4 期
Pharmacokinetics and optimal dosage of caspofungin in critically ill patients with suspected invasive candidiasis.Suspected invasive candidiasissuspected invasive fungal infection10017528NL-OMON40105niversitair Medisch Centrum Groningen20
进行中（未招募）
不适用
Study of the pharmacokinetics and optimal dosage of caspofungin inintensive care patients with a suspected fungal infection.EUCTR2012-003617-34-NLniversity Medical Center Groningen
已完成
4 期
Pharmacokinetics of Caspofungin After One Dose in Patients With Liver FailureBacterial Infections and MycosesLiver DiseaseNCT01968395Erasme University Hospital20
进行中（未招募）
不适用
A phase II dose escalation study of caspofungin in patients with invasive aspergillosis - Caspofungin MTDproven or probable aspergillosis in immunocompromised patientsMedDRA version: 8.1Level: LLTClassification code 10003488Term: AspergillosisEUCTR2006-001936-30-DEniversität zu Köln48